Management of the Non-low-Risk Patients with Febrile Neutropenia
Author:
Klastersky Jean A.
Publisher
Springer Healthcare Ltd.
Reference40 articles.
1. Klastersky J, Ameye L, Maertens, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59.
2. Blot F, Nitenberg G. [High and low-risk febrile neutropenic patients]. Presse Med. 2004;33:467‑473.
3. Ahn S, Lee YS, Chun YH, et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer. 2011;19:1151-1158.
4. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl). 2007;16:475-483.
5. Vänskä M, Koivula I, Jantunen E, et al. IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. Cytokine. 2012;60:787-792.